**Core Concept**
Betaxolol is a β1 selective adrenergic receptor blocker, primarily used in the management of glaucoma. This is because its selective action on β1 receptors minimizes the risk of systemic effects, allowing for topical administration in the eye. The β1 selective blockade reduces aqueous humor production, thereby lowering intraocular pressure.

**Why the Correct Answer is Right**
Betaxolol's β1 selectivity is due to its higher affinity for β1 receptors compared to non-selective β blockers. This characteristic reduces the risk of systemic side effects, such as bradycardia and hypotension, commonly associated with non-selective β blockers. In the eye, the reduction in intraocular pressure is achieved through decreased aqueous humor production, primarily due to the inhibition of adenylate cyclase activity. This leads to a decrease in cyclic AMP levels, resulting in reduced aqueous humor production.

**Why Each Wrong Option is Incorrect**
**Option A:** Levobunolol is a non-selective β blocker, primarily used in glaucoma management. Its lack of β1 selectivity increases the risk of systemic side effects.

**Option B:** Timolol is also a non-selective β blocker, commonly used in glaucoma. Its non-selective action can lead to systemic side effects, making it less ideal for glaucoma management.

**Option D:** Carteolol is a non-selective β blocker with intrinsic sympathomimetic activity (ISA). While it is used in glaucoma, its non-selective action and ISA make it less suitable for patients with certain comorbidities.

**Clinical Pearl / High-Yield Fact**
When selecting a β blocker for glaucoma management, it is essential to consider the patient's systemic health and comorbidities. Non-selective β blockers can increase the risk of systemic side effects, while β1 selective blockers, like betaxolol, offer a safer alternative.

**✓ Correct Answer: C. Betaxolol**